Clinical Trial Detail

NCT ID NCT02409342
Title A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab

Carboplatin

Pemetrexed Disodium

Cisplatin

Age Groups: adult

No variant requirements are available.